Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast

NCT02749370 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02749370
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02749370 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast
Lead sponsor
Amgen
Phase
Phase 4
Overall status
Completed
Start date
May 18, 2016
Completion date
December 6, 2017
Enrollment
80 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis